Published in N Engl J Med on February 24, 2000
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Cancer to bone: a fatal attraction. Nat Rev Cancer (2011) 4.08
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol (2014) 3.02
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Baseline staging tests in primary breast cancer: a practice guideline. CMAJ (2001) 2.22
The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer (2006) 2.14
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer (2011) 1.75
Circulating breast cancer cells are frequently apoptotic. Am J Pathol (2001) 1.72
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res (2008) 1.59
Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer (2006) 1.46
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol (2010) 1.45
Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg (2001) 1.38
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer (2012) 1.33
High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc Natl Acad Sci U S A (2001) 1.32
A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature (2015) 1.30
Pathobiology of brain metastases. J Clin Pathol (2005) 1.29
Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res (2012) 1.27
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res (2008) 1.24
Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer (2009) 1.24
Clinical practice guidelines for the care and treatment of breast cancer: 13. Sentinel lymph node biopsy. CMAJ (2001) 1.19
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer (2003) 1.19
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis (2005) 1.18
Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol (2001) 1.18
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol (2011) 1.13
High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res (2008) 1.12
Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12
Emerging technologies for CTC detection based on depletion of normal cells. Recent Results Cancer Res (2012) 1.09
The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer (2003) 1.09
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res (2011) 1.07
Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer (2012) 1.07
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Circulating tumor cells and DNA as liquid biopsies. Genome Med (2013) 1.06
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer (2011) 1.02
Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res (2012) 1.01
Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res (2011) 1.01
Real-time RT-PCR correlates with immunocytochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Br J Cancer (2004) 1.00
High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg (2006) 1.00
Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem (2002) 1.00
Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. Bonekey Rep (2014) 0.99
Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J Clin Pathol (2007) 0.99
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer (2007) 0.98
Clinical aspects of sentinel node biopsy. Breast Cancer Res (2001) 0.97
The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med (2002) 0.96
Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Patholog Res Int (2011) 0.94
Detection of cancer before distant metastasis. BMC Cancer (2013) 0.94
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer (2013) 0.94
Metabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/B. Oncoimmunology (2015) 0.93
The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications. Clin Exp Metastasis (2012) 0.93
Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res (2004) 0.92
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer (2012) 0.91
Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells? Breast Care (Basel) (2014) 0.90
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS (2008) 0.90
Proteomic technology for biomarker profiling in cancer: an update. J Zhejiang Univ Sci B (2006) 0.90
Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer. Breast Cancer Res (2005) 0.90
Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease. Breast Cancer Res Treat (2012) 0.89
Reliable single cell array CGH for clinical samples. PLoS One (2014) 0.89
Breast cross-examination. CMAJ (2001) 0.88
Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent. PLoS One (2014) 0.88
Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients. J Mol Diagn (2005) 0.87
Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas. Clin Exp Metastasis (2012) 0.87
Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. J Cancer Res Clin Oncol (2009) 0.87
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer (2012) 0.87
Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol (2011) 0.87
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res (2006) 0.86
Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis (2008) 0.86
Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol (2008) 0.85
Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. J Mol Diagn (2005) 0.85
Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int J Breast Cancer (2011) 0.84
The presence of bone marrow cytokeratin-immunoreactive cells does not predict outcome in gastric cancer patients. Br J Cancer (2002) 0.84
Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives. Breast Cancer Res (2004) 0.84
Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer (2012) 0.84
Circulating tumour cells in breast cancer. Ecancermedicalscience (2013) 0.84
Metastasis-Initiating Cells in Renal Cancer. Curr Signal Transduct Ther (2014) 0.83
Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies. Clin Exp Metastasis (2002) 0.83
Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer. J Breast Cancer (2012) 0.82
Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen. Histochem Cell Biol (2005) 0.82
Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer. Br J Cancer (2003) 0.82
[Prognostic and predictive factors of invasive breast cancer: update 2009]. Pathologe (2009) 0.82
Influence of immunomagnetic enrichment on gene expression of tumor cells. J Transl Med (2005) 0.81
Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors. Clin Exp Metastasis (2015) 0.81
Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR. Int J Mol Sci (2013) 0.81
The role and clinical relevance of disseminated tumor cells in breast cancer. Cancers (Basel) (2014) 0.81
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor? J Cancer Res Clin Oncol (2005) 0.80
Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma. Int J Clin Oncol (2014) 0.80
Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas. Breast Cancer Res (2005) 0.79
A reconstructed metastasis model to recapitulate the metastatic spread in vitro. Biotechnol J (2014) 0.79
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15
Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding. Proc Natl Acad Sci U S A (1994) 8.06
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer (1988) 3.66
In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood (2000) 3.57
Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature (1977) 3.46
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 3.24
MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A (1989) 2.82
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet (1989) 2.22
Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet (1992) 2.21
Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst (1993) 2.14
Nck, a melanoma cDNA encoding a cytoplasmic protein consisting of the src homology units SH2 and SH3. Nucleic Acids Res (1990) 2.12
Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biol Chem (1994) 2.08
alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry (1990) 2.03
Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med (1997) 2.03
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol (2000) 1.99
De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A (1989) 1.90
Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res (2001) 1.88
Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet (1996) 1.84
Molecular mechanisms in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci U S A (1990) 1.83
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation (1993) 1.81
Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int (1993) 1.80
Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch (1998) 1.79
The Synthesis and X-ray Structural Characterization of mer and fac isomers of the Technetium(I) Nitrosyl Complex [TcCl(2)(NO)(PNPpr)]. Inorganica Chim Acta (2009) 1.77
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol (1998) 1.77
Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol (1991) 1.76
Borrowing strength with nonexchangeable priors over subpopulations. Biometrics (2011) 1.75
Mapping of immunodominant CD4+ T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology (1995) 1.72
Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant (1997) 1.67
Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy (2009) 1.66
[Current problems in the treatment of gonorrhea]. Schweiz Med Wochenschr (1966) 1.64
Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock (1996) 1.63
p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene (1993) 1.62
A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 1.55
Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res (1987) 1.52
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet (1995) 1.51
Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg (1998) 1.50
[Hypohidrotic ectodermal dysplasia as the cause of recurrent hyperthermia in a young infant]. Kinderarztl Prax (1992) 1.48
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res (2001) 1.48
The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer (1986) 1.47
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A (1995) 1.46
p53 in non-small-cell lung cancer. J Natl Cancer Inst (1994) 1.46
Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res (1999) 1.43
Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol (1991) 1.42
24 hour intragastric acidity and single night-time dose of three H-2-blockers. Lancet (1983) 1.41
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Inhibition of procollagen cell-free synthesis by amino-terminal extension peptides. Biochemistry (1979) 1.40
Subtypes of T-cell chronic lymphatic leukemia. Cancer (1983) 1.39
On the confounding effects of phosphor persistence in oscilloscopic displays. Vision Res (1993) 1.39
Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A (1987) 1.36
MAGE-A gene expression pattern in primary breast cancer. Cancer Res (2001) 1.34
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother (1994) 1.34
Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer (1999) 1.33
Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties. J Med Chem (1990) 1.32
Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol (2001) 1.32
Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer (1991) 1.31
Genomic organization of the melanoma-associated glycoprotein MUC18: implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci U S A (1993) 1.31
Tracking of flying insects using pan-tilt cameras. J Neurosci Methods (2000) 1.30
Direct demonstration of an HLA-DR allotypic determinant on the low molecular weight (beta) subunit using a mouse monoclonal antibody specific for DR3. J Exp Med (1982) 1.29
Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol (2001) 1.28
Antibiotic treatment to prevent urinary tract infections after urodynamic evaluation. Int Urogynecol J Pelvic Floor Dysfunct (2001) 1.28
Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum (1991) 1.28
Involvement of the cytotoxic/suppressor T-cell subset in liver tissue injury of patients with acute and chronic liver diseases. Gastroenterology (1983) 1.26
Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res (1991) 1.25
Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol (2003) 1.25
300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe. Scand J Gastroenterol Suppl (1987) 1.25
The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis. Proc Natl Acad Sci U S A (1992) 1.24
The cellular receptor (CD4) of the human immunodeficiency virus is expressed on neurons and glial cells in human brain. J Exp Med (1987) 1.23
Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol (1996) 1.22
Evaluation of pelvic floor muscle strength using four different techniques. Int Urogynecol J Pelvic Floor Dysfunct (2001) 1.21
Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat (2006) 1.21
Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin. Eur J Immunol (1981) 1.21
In vitro desensitization to lipopolysaccharide suppresses tumour necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology (1992) 1.20
Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations. Immunobiology (1985) 1.20
Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet (1977) 1.19
Dynamics of membrane penetration of the fluorescent 7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD) group attached to an acyl chain of phosphatidylcholine. Biophys J (2001) 1.19
Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int J Cancer (1997) 1.18